A Pilot Randomised Controlled Trial of a Targeted Dietary Approach to Potassium Management in Hemodialysis: A Clinical Research Protocol for the Evidence for Optimal Potassium Intake in Hemodialysis (EvoKe-HD) Study
Canadian Journal of Kidney Health and Disease · 2026-08 · 13
DOI: 10.1177/20543581261476635 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Canadian Journal of Kidney Health and Disease, online erschienen am 19.08.2026. Verfasst von Amélie Bernier-Jean und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre de recherche, CIUSSS du Nord-de-l'Île-de-Montréal, Montreal, QC, Canada. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research, Institute of Nutrition, Metabolism and Diabetes, Fonds de recherche du Québec – Santé.
Abstract (Originalsprache)
Background
Hyperkalemia affects more than one in five patients receiving maintenance hemodialysis and remains a major contributor to arrhythmias and sudden cardiac death. Traditional potassium restriction has centered on limiting fruits and vegetables, even as emerging evidence challenges the assumption that all high-potassium foods pose equal risk. Meanwhile, awareness of potassium additives has grown, and recommendations to avoid additive-containing processed foods have been layered onto existing restrictions. Together, the uncertainties around long-standing to newer recommendations create guidance that is difficult for many patients to navigate.
Objective
To describe the protocol for EvoKe-HD, a pilot randomised controlled trial evaluating the feasibility, acceptability and safety of a targeted dietary counselling strategy for potassium management in hemodialysis.
Design
Two-arm, 1:1 randomised, parallel-group feasibility trial.
Setting
Two dialysis units at the CIUSSS du Nord-de-l’Île-de-Montréal, Canada. Patients Adults receiving thrice-weekly maintenance hemodialysis with elevated pre-dialysis serum potassium levels or receiving regular potassium binder therapy.
Measurements
The primary feasibility outcome is the proportion of eligible patients who enrol and complete the 3-month assessment. The main exploratory clinical outcome is mean mid-week pre-dialysis serum potassium during follow-up. Secondary and exploratory outcomes include hyperkalemia events, potassium binder use, dialysate potassium adjustments, biochemical measures, dietary outcomes, patient-reported outcomes, and process evaluation measures.
Methods
Participants are randomised to monthly targeted dietary counselling focused on reducing potassium additives and selected high-impact foods, or to monthly standard potassium-restriction counselling based primarily on total potassium content. Feasibility outcomes will be summarized with 95% confidence intervals. Mean follow-up serum potassium will be analysed using linear mixed-effects model adjusted for baseline potassium and sex, with a random intercept for participant.
Results
Recruitment began in June 2025 and was completed in January 2026. The last study visit was completed in March 2026. Process evaluation interviews are expected to be completed in July 2026.
Limitations
As a single-centre pilot feasibility trial, EvoKe-HD is not powered to evaluate definitive effects on serum potassium, hyperkalemia events, or other clinical outcomes.
Conclusions
EvoKe-HD will assess whether a targeted potassium counselling strategy can be implemented in routine hemodialysis care and will provide feasibility and process evaluation data to inform the design of a larger trial.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre de recherche, CIUSSS du Nord-de-l'Île-de-Montréal, Montreal, QC, Canada.
- Faculté de médecine, Université de Montréal, Montreal, QC, Canada.
- NHMRC Clinical Trials Centre, Camperdown, NSW, Australia.
- Institut universitaire de cardiologie et de pneumologie de Québec, Quebec, QC, Canada.
- Faculty of Medicine and Health, The University of Sydney School of Public Health, Sydney, NSW, Australia.
- McMaster University Faculty of Health Sciences, Hamilton, ON, Canada.
ORCID-Profile: Amélie Bernier-Jean, Rémi Goupil, Catherine Clase
Förderung
- Canadian Institutes of Health Research, Institute of Nutrition, Metabolism and Diabetes
- Fonds de recherche du Québec – Santé
Zitieren
APA
Bernier-Jean, A., Goupil, R., Madore, F., Dawson, J., Papineau, R., Jaure, A., & Clase, C. (2026). A Pilot Randomised Controlled Trial of a Targeted Dietary Approach to Potassium Management in Hemodialysis: A Clinical Research Protocol for the Evidence for Optimal Potassium Intake in Hemodialysis (EvoKe-HD) Study. Canadian Journal of Kidney Health and Disease, 13. https://doi.org/10.1177/20543581261476635
Vancouver
Bernier-Jean A, Goupil R, Madore F, Dawson J, Papineau R, Jaure A, et al. A Pilot Randomised Controlled Trial of a Targeted Dietary Approach to Potassium Management in Hemodialysis: A Clinical Research Protocol for the Evidence for Optimal Potassium Intake in Hemodialysis (EvoKe-HD) Study. Canadian Journal of Kidney Health and Disease. 2026;13. doi:10.1177/20543581261476635
BibTeX
@article{BernierJean2026,
author = {Bernier-Jean, Amélie and Goupil, Rémi and Madore, François and Dawson, Jessica and Papineau, Roxanne and Jaure, Allison and Clase, Catherine},
title = {A Pilot Randomised Controlled Trial of a Targeted Dietary Approach to Potassium Management in Hemodialysis: A Clinical Research Protocol for the Evidence for Optimal Potassium Intake in Hemodialysis (EvoKe-HD) Study},
journal = {Canadian Journal of Kidney Health and Disease},
year = {2026},
volume = {13},
doi = {10.1177/20543581261476635}
}
EUVIMED